Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
proinsulin II mRNA lipid particle aggregates
- Development stage
- Preclinical
- Lead developer
- University of Florida
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics
- Administration
- Intravenous
01
Overview
Proinsulin II mRNA lipid particle aggregates (LPAs) are an experimental mRNA-based immunotherapy designed to prevent or delay the onset of type 1 diabetes (T1D). The drug consists of murine proinsulin II (PI2) mRNA encapsulated within lipid particles that form aggregates. The mechanism involves the induction of immunotolerance by delivering the proinsulin antigen in a manner that modulates the immune response, specifically by maintaining immunoregulatory cytokine elevations (e.g., IL-10) and reducing proinflammatory cytokines. In preclinical studies using the non-obese diabetic (NOD) mouse model, low doses of these LPAs have been shown to significantly delay T1D onset and reduce disease incidence by suppressing autoimmunity and preserving beta-cell function.
- Other names
- proinsulin II mRNA LPAsPI2 mRNA lipid particle aggregatesPI-2 mRNA lipid particle aggregatesPI 2 mRNA lipid particle aggregates
02
Targets
MHC class II antigen presentation of proinsulin-derived peptidesPRR (Pattern recognition receptors)Proinsulin II-specific T-cell receptor
Beyond the preview
Go deeper on proinsulin II mRNA lipid particle aggregates.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on proinsulin II mRNA lipid particle aggregates.